$PFE Pfizer. Rounded bottom breakoutNice rounded bottom breakout and retest @ $29,30 level. If this level holds the target would be $33,50. 15% Upside on a good dividend payer.
PFE trade ideas
PFE is it completed the Accumulation and Going to Fly ?! It is the first time to break out the wide range since DEC 2023
Now We are in Phase E ( Trading outside the Range) - Wyckoff Method
Supply showing Effort with no result
Demand has Increased
Also there is upcoming earning
so, Is the accumulation phase has completed and we are going to 🚀 ?!
TP 01 : 34.71
TP 02: 37.17
SL: 29.30
I am Just sharing insights and market trends for learning and growing every day and it is not financial advice.
Short Chance. PFIZER (short term) Technical
Earning are deceasing.
I see a lower price/lower earnings cycle popup.
Price is high compaired to a normal reaction for lower earnings. Big buyer drives up the price but this one does not drive the price up. So I think it will reverse when the buyer leaves.
Risk reward short seems higher for me at this point. First Close after the 10D VWAP should be a trigger.
Fundamental
Not in image for this trade horizon.
Long PilledOnce-a-day obesity pill en route. Expect the share price to swell with the anticipation over the years, to the tune of 200%.
Standard 1.618 long term extensions all but guaranteed.
PERFECT TIME TO BUY. $PFE to $32 before Next Earning The falling wedge is a bullish price formation that tells a tale of the stock where bulls are gearing up for a new rally.
+ NYSE:PFE is trading below my estimate of fair value ($68.47). OVERSOLD!
+ Their Earning is expected to return to the $9-10 billion range (Pre-Covid). The current earning is 2.13 billion.
+ Paxlovid, Prevnar, Elliquis, Ibrance, Xeljanz, Enbrel and Zithromax/Zmax continue to be the most effecitive medications.
+ Pfizer, a company that pays dividends, currently has a yield of 6.21%. I have faith in my chart analysis, however, even if there are inconsistencies, dividends will continue to be distributed, which solidifies its attractiveness as a long-term investment opportunity.
Risk-Free & East Gain
PFE - our Long Call materializesOur recent recommended top pick from Healthcare sector: PFE: released better than expected financial results; raised full year guidance;
The company’s earnings per share (EPS) in the second quarter stood at $0.60, surpassing the consensus estimate of $0.46. Revenue came in at $13.3 billion, also above the projected $13.03 billion.
Pfizer reported adjusted research and development expenses of $2.67 billion for the period, compared to the estimated $2.83 billion.
Looking forward, the pharmaceutical giant now projects FY2024 EPS of $2.45 to $2.65, up from the previous guidance of $2.15 to $2.35, and above the consensus estimate of $2.38.
price levels to trade PFE after its earningCertainly! **Pfizer** has been actively advancing its gene therapy pipeline, particularly in the field of hemophilia. Here are some key developments:
1. **Giroctocogene fitelparvovec**:
- Pfizer announced positive topline results from the **Phase 3 AFFINE study** evaluating giroctocogene fitelparvovec. This investigational gene therapy targets **hemophilia A** in adults with moderately severe to severe forms of the condition.
- Key findings:
- Achieved its primary objective of **non-inferiority** and **superiority** compared to routine Factor VIII (FVIII) replacement prophylaxis treatment.
- Demonstrated a statistically significant reduction in mean total annualized bleeding rate (ABR) compared to the pre-infusion period.
- Most participants maintained FVIII activity >5% at 15 months post-infusion.
- Generally well-tolerated, with no impact on efficacy and safety results¹.
- Notably, Pfizer also received FDA approval for **Beqvez**, a gene therapy for **hemophilia B**.
- Additionally, regulatory submissions for **marstacimab** as a potential treatment for both hemophilia A and B are underway in the U.S. and Europe².
2. **Other Gene Therapy Programs**:
- Pfizer currently has three Phase 3 programs investigating gene therapy in populations with high unmet needs:
- **Hemophilia B**
- **Hemophilia A**
- **Duchenne muscular dystrophy**³.
Pfizer's commitment to advancing gene therapies holds great promise for patients worldwide. 🌟🧬⁴⁵ 🚀
Source: Conversation with Copilot, 7/30/2024
(1) Pfizer Announces Positive Topline Results From Phase 3 Study of .... www.pfizer.com
(2) Pfizer Hemophilia Gene Therapy Meets Phase 3 Goals, But Its Success .... medcitynews.com
(3) Pfizer Announces Positive Top-Line Results from Phase 3 Study of .... www.pfizer.com
(4) Pfizer Pipeline. cdn.pfizer.com
(5) New Drug Development Pipeline: Pfizer's Medicine, Vaccine Discovery .... www.pfizer.com
White oscillation range rises and breaks throughWhite oscillation range rises and breaks through
There are also yellow oscillation intervals and blue downward channels
$PFE long ideaSome significant support here on the weekly chart. I got in a few days ago.. Risk reward ratio worth the long here. Always manage risk so you can live to trade another day! This is not financial advice of course. Please do your own research & Happy Trading!
PFE LongPFE as market a local bottom in my opinion. It breached the lows of a long consolidation and reversed soon after. It also seems to be forming a triangle on the monthly timeframe
PFEPFE consolidates after a flat correction. Larger frame analysis is in the updates below.
Tracking this stock for a long time. Now its time to go up
Manage your risk. Don't overconcentrate individual positions, let them concentrate themselves as the winners grow.
PFE breakout PossibleHolding strong support
29 above trendline breakout Possible
31/33/36 can test soon
Pfizer (PFE) AnalysisOverview:**
Pfizer Inc. (PFE) has been in a prolonged downtrend but is showing signs of potential recovery. The recent chart indicates a bounce from the lows, with key technical indicators suggesting a possible reversal.
**Technical Analysis:**
1. **Fibonacci Retracement Levels**:
- The chart shows Fibonacci retracement levels drawn from the recent high to the low. The stock has rebounded from the lower levels and is currently testing the 23.6% retracement level around $29.50. A sustained break above this level could target the next resistance levels at $32 and $35.
2. **Moving Averages**:
- The stock has moved above the short-term moving averages (indicated by the green and blue lines), which suggests bullish momentum. If it can maintain above these levels, it could attract more buying interest.
3. **MACD and RSI**:
- The MACD indicator shows a bullish crossover, and the histogram has turned positive, indicating increasing bullish momentum.
- The RSI is rising from oversold territory, currently at 87.03, which suggests strong buying pressure but also warrants caution as it nears overbought levels.
**Fundamental Perspective:**
- **Recent Developments**:
Pfizer's ongoing developments in its drug pipeline, including advancements in COVID-19 treatments and vaccines, continue to provide long-term growth potential. Investors should keep an eye on upcoming earnings reports and updates on key products.
- **Valuation**
The current price level may represent a value opportunity given Pfizer's strong balance sheet and consistent dividend payments. The company has a history of generating significant free cash flow, which supports its ability to invest in new research and return capital to shareholders.
**Conclusion:**
Pfizer appears to be at a crucial juncture, with technical indicators suggesting a potential trend reversal. Investors should monitor the $29.50 level for a possible breakout and consider the broader market conditions and Pfizer’s upcoming announcements for further confirmation of the bullish trend.
**Risk Management:**
- Set stop-loss orders below recent lows to manage downside risk.
- Consider scaling into the position to mitigate the impact of volatility.
**Disclaimer**: This analysis is for informational purposes only and should not be considered as financial advice.
Dr SAUD
Pfizer Big buy opportunity!After long time of sell pfizer has reached a really good buy opportunity!
buy now for a 20.59 R/R
Pfizer: This sell off is nowhere near finished
Pfizer has been getting pushed like crazy on CNBC by fund managers like Josh Brown as a good buy and after looking at the charts above its very easy to see why. Wallstreet pricks like Brown are trying to offload their last remaining shares on unsuspecting retail buyers.
As you can see in the first chart on the daily timeframe, Pfizer is below the 200 and tried 3 different times to get above it and failed. In the second chart on the monthly timeframe, Pfizer is now below the 200 on the Monthly and is now consolidating, the last time this happened was back in 2009 and after consolidating below the 200 for 3 months, it tanked 50% for 15 months in a row, from $22.50 down to just under $13 a share. Pfizer will not be a buy for a long long time
NYSE:PFE
Ready to explode!We have everything in place…
A double bottom
A channel down breakout
An inverted head and shoulder forming out
PFE - Will The Strong Downtrend Ever Be Retested? My thoughts showing how an extended bear move could result in the downward test of a previous bear trend line
I do expect however that one of the green trend lines will hodl so I have put price labels on each of those. It is more likely to continue up than to make this horrid move.
Imagine it going down to $3!
PFE Long 1D Conservative Trade DCAConservative Trade
"+ long balance
- volumed expanding ICE
+ support level
+ volumed 2Sp-"
Monthly context
"- short impulse
+ 1/2 correction of 15 years long trend
+ historical volume
- resistance level"
There's no trading signal, but I like volume distribution on daily, so started to accumulate shares little by little.
No stop loss or take profit at this point, we'll be adding as we go.
peeking $PFE's levels to manage my positionPfizer Inc. is the best gene therapy stock to buy now.
Pfizer expects an FDA decision for Marstacimab, a potential once-weekly subcutaneous treatment for hemophilia B. They also started a Phase 3 study for osivelotor in sickle cell disease.
New Product Approvals: Pfizer’s recent product approvals include Abrysvo RSV vaccine, Velsipity (etrasimod) for ulcerative colitis, Penbraya pentavalent meningococcal vaccine, Zavzpret nasal spray for migraine, Litfulo (ritlecitinib) for severe alopecia areata, and Beqvez (fidanacogene elaparvovec), a one-time gene therapy for hemophilia B.
Pfizer Inc ideaPfizer Inc idea
Safe to enter above $27.18
we may see a new low below $25
Technicals are on positive side..
Pfizer !!! low risk , 20% Gain till next month ?? Hello everyone, today I want to discuss Pfizer's stock which experienced a 58% correction from its peak price and is currently trading around $26. I believe this stock has a lot of potential for both scalpers and long-term investors. With a dividend yield of 6.65% at this price, it's an attractive investment option. Additionally, the earnings report due this week could boost the stock price to $30 by next month. You can refer to the chart for trade stop and stop-loss points.
Disclaimer: This information or service is for informational purposes only and is not
intended to be personal financial advice
#pfizer
Buying Pfizer!! is it a good moment?? what's the upside ??Details are on the chart as always.
Along term buy for me personally I guess. This is not an advise to buy or sell any stock.
learning the strategies to improve.
